Windtree Therapeutics (WINT) Stock Price

Windtree Therapeutics Price

NASDAQ·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Over the last 14 years Windtree Therapeutics grew revenue by 2.8% annually, reaching 198,000.00 USD. For Windtree Therapeutics, the net margin of -13,876.3% is down versus -5,589.7% a few years ago. The consensus 12-month price target for Windtree Therapeutics is 180.54 USD, about 90,269,902.3% above where the stock trades today. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 300% above its 52-week low.

Windtree Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Windtree Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Windtree Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Windtree Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Windtree Therapeutics Stock Price History
DateWindtree Therapeutics Price
8/12/20260.00 USD
8/11/20260.00 USD
8/10/20260.00 USD
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.01 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.01 USD
7/10/20260.01 USD
7/9/20260.01 USD
7/8/20260.01 USD
7/7/20260.01 USD
7/6/20260.01 USD
7/2/20260.01 USD
7/1/20260.01 USD
6/30/20260.01 USD
6/29/20260.01 USD
6/26/20260.01 USD
6/25/20260.01 USD
6/24/20260.01 USD
6/23/20260.01 USD
6/22/20260.01 USD
6/18/20260.01 USD
6/17/20260.01 USD
6/16/20260.01 USD
6/15/20260.01 USD
6/12/20260.01 USD
6/11/20260.01 USD
6/10/20260.01 USD
6/9/20260.01 USD
6/8/20260.01 USD
6/5/20260.01 USD
6/4/20260.01 USD
6/3/20260.01 USD
6/2/20260.01 USD
6/1/20260.01 USD
5/29/20260.01 USD
5/28/20260.00 USD
5/27/20260.01 USD
5/26/20260.00 USD
5/22/20260.01 USD
5/21/20260.01 USD
5/20/20260.01 USD
5/19/20260.01 USD
5/18/20260.01 USD
5/15/20260.01 USD
5/14/20260.01 USD
5/13/20260.01 USD
5/12/20260.01 USD
5/11/20260.01 USD
5/8/20260.01 USD
5/7/20260.01 USD
5/6/20260.01 USD
5/5/20260.01 USD
5/4/20260.01 USD
5/3/20260.01 USD
5/1/20260.01 USD
4/30/20260.01 USD
4/29/20260.01 USD
4/28/20260.01 USD
4/27/20260.01 USD
4/24/20260.01 USD
4/23/20260.01 USD
4/22/20260.01 USD
4/21/20260.01 USD
4/20/20260.01 USD
4/17/20260.01 USD
4/16/20260.01 USD
4/15/20260.01 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.01 USD
4/9/20260.01 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.01 USD
3/18/20260.01 USD
3/17/20260.01 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.01 USD
3/5/20260.01 USD
3/4/20260.01 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.01 USD
2/2/20260.01 USD
1/30/20260.01 USD
1/29/20260.01 USD
1/28/20260.01 USD
1/27/20260.01 USD
1/26/20260.01 USD
1/23/20260.01 USD
1/22/20260.01 USD
1/21/20260.01 USD
1/20/20260.01 USD
1/16/20260.01 USD
1/15/20260.01 USD
1/14/20260.01 USD
1/13/20260.01 USD
1/12/20260.01 USD
1/9/20260.01 USD
1/8/20260.01 USD
1/7/20260.01 USD
1/6/20260.01 USD
1/5/20260.01 USD
1/2/20260.01 USD
12/31/20250.01 USD
12/30/20250.01 USD
12/29/20250.01 USD
12/26/20250.01 USD
12/24/20250.02 USD
12/23/20250.02 USD
12/22/20250.02 USD
12/19/20250.02 USD
12/18/20250.02 USD
12/17/20250.02 USD
12/16/20250.02 USD
12/15/20250.03 USD
12/12/20250.03 USD
12/11/20250.03 USD
12/10/20250.03 USD
12/9/20250.03 USD
12/8/20250.03 USD
12/5/20250.03 USD
12/4/20250.03 USD
12/3/20250.03 USD
12/2/20250.03 USD
12/1/20250.03 USD
11/28/20250.02 USD
11/26/20250.03 USD
11/25/20250.03 USD
11/24/20250.03 USD
11/21/20250.03 USD
11/20/20250.03 USD
11/19/20250.03 USD
11/18/20250.03 USD
11/17/20250.03 USD
11/14/20250.04 USD
11/13/20250.03 USD
11/12/20250.04 USD
11/11/20250.04 USD
11/10/20250.04 USD
11/7/20250.04 USD
11/6/20250.04 USD
11/5/20250.04 USD
11/4/20250.04 USD
11/3/20250.05 USD
10/31/20250.05 USD
10/30/20250.05 USD
10/29/20250.05 USD
10/28/20250.05 USD
10/27/20250.06 USD
10/24/20250.06 USD
10/23/20250.06 USD
10/22/20250.05 USD
10/21/20250.06 USD
10/20/20250.05 USD
10/17/20250.06 USD
10/16/20250.06 USD
10/15/20250.07 USD
10/14/20250.08 USD
10/13/20250.09 USD
10/10/20250.09 USD
10/9/20250.07 USD
10/8/20250.06 USD
10/7/20250.05 USD
10/6/20250.05 USD
10/3/20250.04 USD
10/2/20250.04 USD
10/1/20250.04 USD
9/30/20250.04 USD
9/29/20250.04 USD
9/26/20250.04 USD
9/25/20250.04 USD
9/24/20250.04 USD
9/23/20250.04 USD
9/22/20250.04 USD
9/19/20250.04 USD
9/18/20250.04 USD
9/17/20250.04 USD
9/16/20250.04 USD
9/15/20250.03 USD
9/12/20250.03 USD
9/11/20250.03 USD
9/10/20250.04 USD
9/9/20250.04 USD
9/8/20250.04 USD
9/5/20250.04 USD
9/4/20250.04 USD
9/3/20250.04 USD
9/2/20250.03 USD
8/29/20250.03 USD
8/28/20250.03 USD
8/27/20250.03 USD
8/26/20250.03 USD
8/25/20250.04 USD
8/22/20250.04 USD
8/21/20250.04 USD
8/20/20250.03 USD
8/19/20250.03 USD
8/18/20250.03 USD
8/15/20250.04 USD
Access this data via the Eulerpool API
Get Free API Key

Windtree Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
198,000.00 USD
-26.98 M USD
-27.48 M USD
Jan 1, 2020
0.00 USD
-32.44 M USD
-30.28 M USD
Jan 1, 2021
0.00 USD
-77.51 M USD
-67.64 M USD
Jan 1, 2022
0.00 USD
-41.33 M USD
-39.21 M USD
Jan 1, 2023
0.00 USD
-17.54 M USD
-20.29 M USD
Jan 1, 2024
0.00 USD
-25.02 M USD
-5.49 M USD
Jan 1, 2025 (e)
12.20 M USD
-19.41 M USD
-37.70 M USD
Jan 1, 2026 (e)
12.40 M USD
-36.11 M USD
-42.55 M USD

Windtree Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:25 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201120122013201420152016201720182019202020212022202320242025e2026e
–––2.00–2.001.001.00––––––12.0012.00
––––––-50.00–––––––––
–––-50.00–50.00-1,500.00-800.00––––––-8.33-8.33
-1.00-1.00-1.00-1.00-1.001.00-15.00-8.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00
-24.00-37.00-44.00-43.00-39.00-36.00-22.00-19.00-26.00-32.00-77.00-41.00-17.00-25.00-19.00-36.00
–––-2,150.00–-1,800.00-2,200.00-1,900.00––––––-158.33-300.00
-20.00-37.00-45.00-44.00-55.00-39.00-18.00-20.00-27.00-30.00-67.00-39.00-20.00-5.00-37.00-42.00
5.2685.0021.62-2.2225.00-29.09-53.8511.1135.0011.11123.33-41.79-48.72-75.00640.0013.51
0.260.260.260.26––2.427.221.151.772.67–0.010.260.260.26
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Windtree Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Windtree Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Windtree Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Windtree Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Windtree Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Windtree Therapeutics stock margins

The Windtree Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Windtree Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Windtree Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
93.59 %
-13,626.26 %
-13,876.26 %
Jan 1, 2020
93.59 %
- %
- %
Jan 1, 2021
93.59 %
- %
- %
Jan 1, 2022
93.59 %
- %
- %
Jan 1, 2023
93.59 %
- %
- %
Jan 1, 2024
93.59 %
- %
- %
Jan 1, 2025 (e)
93.59 %
-159.10 %
-309.05 %
Jan 1, 2026 (e)
93.59 %
-291.19 %
-343.13 %

Windtree Therapeutics Stock Revenue, EBIT, Earnings per Share

The Windtree Therapeutics earnings per share therefore indicates how much revenue Windtree Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2019
8.58 USD
-1,169.08 USD
-1,190.53 USD
Jan 1, 2020
0.00 USD
-916.67 USD
-855.61 USD
Jan 1, 2021
0.00 USD
-1,451.26 USD
-1,266.40 USD
Jan 1, 2022
0.00 USD
-2.30 M USD
-2.18 M USD
Jan 1, 2023
0.00 USD
-130,888.06 USD
-151,425.38 USD
Jan 1, 2024
0.00 USD
-4,878.90 USD
-1,070.01 USD
Jan 1, 2025 (e)
7,870.97 USD
-3,785.22 USD
-24,325.00 USD
Jan 1, 2026 (e)
8,000.00 USD
-7,041.34 USD
-27,450.00 USD

Windtree Therapeutics business model & stock analysis

Windtree Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Windtree Therapeutics Employees
Details
Date
Windtree Therapeutics Employees
Jan 1, 2017
- Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees

Windtree Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Windtree Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Windtree Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Windtree Therapeutics shares outstanding

The number of shares of Windtree Therapeutics was 5,128 in 2025. This indicates how many shares Windtree Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2019
23,078.00 Stocks
Jan 1, 2020
35,390.00 Stocks
Jan 1, 2021
53,408.00 Stocks
Jan 1, 2022
18.00 Stocks
Jan 1, 2023
134.00 Stocks
Jan 1, 2024
5,128.00 Stocks
Jan 1, 2025 (e)
5,128.00 Stocks
Jan 1, 2026 (e)
5,128.00 Stocks

Windtree Therapeutics stock splits

In Windtree Therapeutics's history, there have been no stock splits.

Current Windtree Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
50.00 % (3)
Sell
50.00 % (3)
12M Price Target
180.54
Last Price
0.00
Currency
USD
12M Return Potential
90,269,902.28 %
LTM Return
0 %

Windtree Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
12/4/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedNeutral–
6/4/2021
Oppenheimer
Oppenheimer
MaintainedOutperform65
11/25/2020
Ladenburg Thalmann
Ladenburg Thalmann
MaintainedBuy–
11/25/2020
H.C. Wainwright
H.C. Wainwright
MaintainedBuy–
6/26/2020
Ladenburg Thalmann
Ladenburg Thalmann
MaintainedBuy–
6/30/2017
Stifel Nicolaus
Stifel Nicolaus
DowngradeBuyHold–
4/22/2016
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
4/22/2016
H.C. Wainwright
H.C. Wainwright
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Windtree Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
4/13/20260.02USD-3.88 MUSD-2025 Q4
11/28/2025-0.06USD-3.26 MUSD-2025 Q3
8/18/2025-0.11USD-3.06 MUSD-2025 Q2
11/7/2024-2.32USD-0.00USD-2024 Q3
5/13/2024-0.56USD-0.00USD-2024 Q1
3/29/2024-0.62USD-0.00USD-2023 Q4
11/13/2023-0.17USD-385,699.00USD-2023 Q3
8/9/2023-0.22USD-304,499.00USD-2023 Q2
5/3/2023-0.23USD-202,999.00USD-2023 Q1
3/29/2023-0.01USD-7.66 MUSD-2022 Q4
...

Windtree Therapeutics shareholder structure

% Name
0.00258%
Strobeck (Mark)
Strobeck (Mark)
0.00129%
Curtis (Eric)
Curtis (Eric)
0.00000%
Jane Street Capital, L.L.C.
Jane Street Capital, L.L.C.
0.00000%
SBI Securities Co., Ltd.
SBI Securities Co., Ltd.
0.00000%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.00000%
Tower Research Capital LLC
Tower Research Capital LLC

Windtree Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
100.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
42.80%
94-3171940
94-3171940
SEC ↗
13.81%
Robert J. Capetola, Ph.D.
Robert J. Capetola, Ph.D.
SEC ↗
13.00%
FMR LLC
FMR LLC
SEC ↗
13.00%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
9.99%
Rockledge Capital Corporation
Rockledge Capital Corporation
SEC ↗
9.99%
Lincoln Park Capital, LLC
Lincoln Park Capital, LLC
SEC ↗
9.99%
Joshua B. Scheinfeld
Joshua B. Scheinfeld
SEC ↗
9.99%
Jonathan I. Cope
Jonathan I. Cope
SEC ↗
9.99%
Alex Noah Investors, Inc.
Alex Noah Investors, Inc.
SEC ↗
9.90%
Lind Global Partners II LLC
Lind Global Partners II LLC
SEC ↗

Windtree Therapeutics Executives and Management Board

4 members · avg. age 51 · 25 % women

JL

Mr. Jed Latkin (50)

President, Chief Executive Officer, Director · since 2024

69,021.00 USD

MS

Dr. Mark Strobeck (54)

Independent Chairman of the Board

56,215.00 USD
SP

Ms. Saundra Pelletier (55)

Independent Director

23,372.00 USD
AK

Mr. Andrew Kucharchuk (44)

Independent Director

–

Frequently asked questions about Windtree Therapeutics

Analysts currently set an average price target of 180.54 USD for the Windtree Therapeutics stock (median: 180.54 USD), implying +90.3 M % versus the latest price. The consensus is based on 6 analyst ratings.

Windtree Therapeutics Analyst Price Targets 2026

6 analysts currently rate the Windtree Therapeutics stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Windtree Therapeutics to generate revenue of 12.40 M USD and earnings per share of -8,297.09 USD.

Windtree Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Windtree Therapeutics share trades at 0.00 EUR (0.00 USD).

The Windtree Therapeutics share (WINT) is listed on 1 stock exchanges, including: NASDAQ (WINT).

No history available for Windtree Therapeutics.

The expected revenue of Windtree Therapeutics is 12.40 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Windtree Therapeutics is -42.55 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Windtree Therapeutics is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Windtree Therapeutics stock.

The price-to-sales ratio (P/S) of Windtree Therapeutics is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Windtree Therapeutics stock.

The Eulerpool Quality Score for Windtree Therapeutics is 2/10.

The ISIN of Windtree Therapeutics is US97382D6004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Windtree Therapeutics is A2P3ZQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Windtree Therapeutics is WINT. The ticker symbol is used to trade Windtree Therapeutics shares on the stock exchange.

Windtree Therapeutics paid dividends every year for the past 0 years.

Windtree Therapeutics is assigned to the 'Health' sector.

The dividends of Windtree Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Windtree Therapeutics

Our stock analysis for Windtree Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Windtree Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Windtree Therapeutics Stock
Windtree Therapeutics Revenue→
Windtree Therapeutics Stock
Windtree Therapeutics Net Income→
Windtree Therapeutics Stock
Windtree Therapeutics P/E→
Windtree Therapeutics Stock
Windtree Therapeutics P/S→
Windtree Therapeutics Stock
Windtree Therapeutics EBIT→
Windtree Therapeutics Stock
Windtree Therapeutics Dividend→
Windtree Therapeutics Stock
Windtree Therapeutics Directors Dealings→
Windtree Therapeutics Stock
Windtree Therapeutics Stocks→
Windtree Therapeutics Stock
Windtree Therapeutics Market capitalization→
Windtree Therapeutics Stock
Windtree Therapeutics Debt→
Windtree Therapeutics Stock
Windtree Therapeutics Liabilities→
Windtree Therapeutics Stock
Windtree Therapeutics Equity→
Windtree Therapeutics Stock
Windtree Therapeutics AAQS→
Windtree Therapeutics Stock
Windtree Therapeutics Employees→
Windtree Therapeutics Stock
Windtree Therapeutics ROE→
Windtree Therapeutics Stock
Windtree Therapeutics ROA→
Windtree Therapeutics Stock
Windtree Therapeutics ROCE→
Windtree Therapeutics Stock
Windtree Therapeutics News→
Windtree Therapeutics Stock
Windtree Therapeutics Analyst Price Targets→

Health Stocks

Winner Medical CoWindlas BiotechWinnergy Medical PCLWin-Partners CoWinning Health Technology Group CoWiltrom CoWinston Medical Supply CoWhitehawk TherapeuticsWinston PharmaceuticalsWhanin Pharm CoWithus Pharmaceutical CoWest Pharmaceutical ServicesAll Stocks A–Z →